Abstract:Park et al1Park S.W. Lee K.J. Chung M.J. et al.Covered versus uncovered double bare self-expandable metal stent for palliation of unresectable extrahepatic malignant biliary obstruction: a randomized controlled multicenter trial.Gastrointest Endosc. 2023; 97: 132-142.e2Abstract Full Text Full Text PDF Scopus (2) Google Scholar reported no significant differences in the 6-month stent patency rates and mortality between partially covered and uncovered double bare self-expandable metal stents (PCDBSs vs UCDBSs) for unresectable distal malignant biliary obstruction. This randomized controlled multicenter trial is of great significance for clinical practice, yet we would like to share our reservations for further research. First, as shown in the baseline characteristics section, the length of the stricture was longer in PCDBSs than in UCDBSs (2.8 ± 1.3 vs 2.4 ± 1.2, P = .010). The length or the degree of stricture might be correlated with disease severity and stent patency,2Kim H.S. Lee D.K. Kim H.G. et al.Features of malignant biliary obstruction affecting the patency of metallic stents: a multicenter study.Gastrointest Endosc. 2002; 55: 359-365Abstract Full Text Full Text PDF PubMed Scopus (92) Google Scholar and longer biliary stricture was an independent risk factor for worse survival after metal stent insertion,3Zu Q.Q. Zhang J.X. Wang B. et al.Percutaneous transpapillary biliary stent placement for distal malignant biliary obstruction: outcomes and survival analysis.Turk J Gastroenterol. 2019; 30: 714-721Crossref Scopus (5) Google Scholar which is also in accord with the fact that the rate of tumor overgrowth was higher in the PCDBS group than in the UCDBS group (5.5% vs 0.8%). Therefore, we hypothesize that the PCDBS group had selection bias, which would weaken the effect of PCDBSs on stent patency and overall survival, and a propensity-matching analysis may be required. Second, we would like to know whether there was a significant difference in the total incidence of single adverse events between the 2 groups, regardless of the 2-week time limit, so as to better verify the overall impact of whether or not the novel metal stent is covered on the risk of adverse events.4Dumonceau J.M. Kapral C. Aabakken L. et al.ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) guideline.Endoscopy. 2020; 52: 127-149Crossref PubMed Scopus (331) Google Scholar Third, the authors did not disclose the details of revision for stent dysfunction, which might have had some influence on stent patency and overall survival. For example, radiofrequency ablation can be performed by both endoscopic and percutaneous routes. As a novel adjunctive procedure and a promising therapeutic option in patients with malignant biliary obstruction, radiofrequency ablation can achieve local tumor control, resulting in improved biliary stent patency and a potential survival benefit.5Inoue T. Yoneda M. Updated evidence on the clinical impact of endoscopic radiofrequency ablation in the treatment of malignant biliary obstruction.Dig Endosc. 2022; 34: 345-358Crossref PubMed Scopus (22) Google Scholar Both authors disclosed no financial relationships.

The performance of biliary stents in malignant biliary strictures

Clinical Application of Endoscopic Metal Biliary Endoprosthesis for Treatment of Malignant Biliary Obstruction

Efficacy and safety of covered versus uncovered self‑expandable metal stents for the palliative treatment of malignant distal biliary stricture: A long‑term retrospective study

S173 Metal Stents Prove Superior to Plastic Stents in Managing Biliary Strictures: A Systematic Review

Adjuvant endobiliary radio-frequency ablation combined with self-expandable biliary metal stents for unresectable malignant hilar strictures: A pragmatic comparative study

A Case Series: Outcomes of Endoscopic Biliary Self-Expandable Metal Stent for Malignant Biliary Obstruction with Surgically Altered Anatomy

Evaluation of post-ERCP pancreatitis after biliary stenting with self-expandable metal stents vs. plastic stents in benign and malignant obstructions

Retrospective comparison of different percutaneous approaches to manage occluded primary uncovered self-expandable metal stents in patients with unresectable malignant hilar biliary obstruction.

Effect of Covered Self-Expanding Metal Stents Compared with Multiple Plastic Stents on Benign Biliary Stricture A Meta-Analysis

Evaluating optimal bilateral biliary stenting in endoscopic reintervention after initial plastic stent dysfunction for unresectable malignant hilar biliary obstruction: Retrospective cross‐sectional study

S1658 Risk Factors for Cholecystitis After Self-Expandable Metallic Stent Placement for Malignant Distal Biliary Obstruction: A Systematic Review and Meta-Analysis

Temporary placement of covered self-expandable metal stents in benign biliary strictures: a new paradigm? (with video)

Iodine-125 Seeds Combined with Biliary Stent Placement Versus Stent Placement Alone for Unresectable Malignant Biliary Obstruction: A Meta-Analysis of Randomized Controlled Trials

Percutaneous Biliary Metallic Stent Insertion in Patients with Malignant Duodenobiliary Obstruction: Outcomes and Factors Influencing Biliary Stent Patency

A Short Fully Covered Self-Expandable Metal Stent for Management of Benign Biliary Stricture Not Caused by Living-Donor Liver Transplantation

Randomized multicenter study of multiple plastic stents vs. covered self-expandable metallic stent in the treatment of biliary stricture in chronic pancreatitis

Safety and efficacy of biliary suprapapillary metal and plastic stents in malignant biliary obstruction: a systematic review and meta-analysis

Outcomes of multi-hole self-expandable metal stents versus fully covered self-expandable metal stents for malignant distal biliary obstruction in unresectable pancreatic cancer

Feasibility of Double-Deployment Small-Diameter Covered Metallic Stent for Malignant Distal Biliary Obstruction (with Video)

Double Bare Self-Expandable Metal Stent for Distal Malignant Biliary Obstruction.

Endoscopic stenting for palliation of malignant biliary obstruction. A review of progress in the last 15 years